Paxlovid rebound patient showed no drug resistance or impaired immunity – Pharmacology and Drug News
Paxlovid is the main oral medicine to prevent severe cases of COVID-19 in people at high risk. However, symptoms returned in some patients after treatment ended, prompting the Centers for Disease Control and Prevention (CDC) to issue a health advisory about this so-called “COVID-19 rebound.” In a study published June 20, 2022 in Clinical infectious …